Quick Answer
Niagen Bioscience, Inc. reported R&D Expense of $6.33 million for fiscal year 2025.
Niagen Bioscience, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.33M | +5.2% |
| 2024 | $6.02M | +21.3% |
| 2023 | $4.96M | +2.7% |
| 2022 | $4.83M | +25.9% |
| 2021 | $3.83M | +12.2% |
| 2020 | $3.42M | -22.7% |
| 2019 | $4.42M | -19.3% |
| 2018 | $5.48M | +36.7% |
| 2017 | $4.01M | +58.8% |
| 2016 | $2.52M | +182.9% |
| 2015 | $891.6K | +73.6% |
| 2014 | $513.7K | +283.2% |
| 2013 | $134.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.79M | +39.1% | +14.6% |
| June 30, 2025 | $1.57M | +19.1% | +24.6% |
| March 31, 2025 | $1.26M | -40.0% | -2.5% |
| September 30, 2024 | $1.29M | +3.9% | -2.0% |
| June 30, 2024 | $1.32M | -3.6% | -37.2% |
| March 31, 2024 | $2.10M | +75.6% | +68.8% |
| September 30, 2023 | $1.24M | +1.4% | -9.1% |
| June 30, 2023 | $1.36M | +9.6% | +14.4% |
- Niagen Bioscience, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Niagen Bioscience, Inc.’s r&d expense has grown by 4622.5% (from $134.0 thousand to $6.33 million).
- The most recent figure is from Niagen Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: